A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
Advanced Science · 2023-11 · 10 (32)
DOI: 10.1002/advs.202302377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 12.10.2023. Verfasst von Xuwei Hong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, P. R. China. Hauptthemen laut MEDLINE: Immunoconjugates, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Medical Research Foundation.
Abstract (Originalsprache)
More than half of non‐muscle‐invasive bladder cancer (NMIBC) patients eventually relapse even if treated with surgery and BCG without optional bladder‐preserving therapy. This study aims to investigate the antitumor activity and safety of a HER2‐targeted antibody‐drug conjugate, RC48‐ADC, intravesical instillation for NMIBC treatment. In this preclinical study, it is revealed that human epidermal growth factor receptor 2 (HER2) expression scores of 1+, 2+, and 3+ are recorded for 16.7%, 56.2%, and 14.6% of NMIBC cases. The antitumor effect of RC48‐ADC is positively correlated with HER2 expression in bladder cancer (BCa) cell lines and organoid models. Furthermore, RC48‐ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase‐dependent apoptosis. In an orthotopic BCa model, tumor growth is significantly inhibited by intravesical instillation of RC48‐ADC versus disitamab, monomethyl auristatin E, epirubicin, or phosphate‐buffered saline control. The potential toxicity of intravesical RC48‐ADC is also assessed by dose escalation in normal nude mice and revealed that administration of RC48‐ADC by intravesical instillation is safe within the range of effective therapeutic doses. Taken together, RC48‐ADC demonstrates promising antitumor effects and safety with intravesical administration in multiple preclinical models. These findings provide a rational for clinical trials of intravesical RC48‐ADC in NMIBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, P. R. China.
- Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510120, P. R. China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510120, P. R. China.
- Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510120, P. R. China.
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510120, P. R. China.
- BioMed Laboratory, Guangzhou Jingke Biotech Group, Guangzhou, Guangdong, 510120, P. R. China.
ORCID-Profile: Yonghai Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangdong Medical Research Foundation
- Science and Technology Program of Guangzhou
- Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- Guangdong Provincial Clinical Research Centre
- Guangdong Science and Technology Department
- Science and Technology Planning Project of Guangdong Province
Zitieren
APA
Hong, X., Chen, X., Wang, H., Xu, Q., Xiao, K., Zhang, Y., Chi, Z., Liu, Y., Liu, G., Li, H., Fang, J., Lin, T., & Zhang, Y. (2023). A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. Advanced Science, 10(32). https://doi.org/10.1002/advs.202302377
Vancouver
Hong X, Chen X, Wang H, Xu Q, Xiao K, Zhang Y, et al. A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. Advanced Science. 2023;10(32). doi:10.1002/advs.202302377
BibTeX
@article{Hong2023,
author = {Hong, Xuwei and Chen, Xu and Wang, Hongjin and Xu, Qingchun and Xiao, Kanghua and Zhang, Yuanfeng and Chi, Zepai and Liu, Yeqing and Liu, Guangyao and Li, Hong and Fang, Jianmin and Lin, Tianxin and Zhang, Yonghai},
title = {A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {32},
doi = {10.1002/advs.202302377}
}
EUVIMED